Browse by Title

Type here to filter the list

E
Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten, Metrum Research Group (METRUM002)
Favorite

Bill Gillespie ### 2343521###Speaker#########
Speaker: Bill Gillespie
### @@@ Tim Waterhouse, PhD (he/him/his) – Metrum Research Group ### 2343522###Speaker###Group Leader Statistics, Principal Scientist II###Metrum Research Group###
Speaker: Tim Waterhouse, PhD (he/him/his) – Metrum Research Group
### he/him/his @@@ Curtis Johnston, PharmD – Metrum Research Group ### 2343523###Speaker###Group Leader, Principal Scientist II, PKPD M&S###Metrum Research Group###
Speaker: Curtis Johnston, PharmD – Metrum Research Group
### @@@ Seth Green ### 2343524###Speaker#########
Speaker: Seth Green
### METRUM002
Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten, Metrum Research Group (METRUM001)
Favorite

Bill Gillespie ### 2343521###Speaker#########
Speaker: Bill Gillespie
### @@@ Tim Waterhouse, PhD (he/him/his) – Metrum Research Group ### 2343522###Speaker###Group Leader Statistics, Principal Scientist II###Metrum Research Group###
Speaker: Tim Waterhouse, PhD (he/him/his) – Metrum Research Group
### he/him/his @@@ Curtis Johnston, PharmD – Metrum Research Group ### 2343523###Speaker###Group Leader, Principal Scientist II, PKPD M&S###Metrum Research Group###
Speaker: Curtis Johnston, PharmD – Metrum Research Group
### @@@ Seth Green ### 2343524###Speaker#########
Speaker: Seth Green
### METRUM001
Embracing modern programming tools for pharmacometrics (PMx) dataset creation, review and reporting
Favorite

Jing Su, MS – Merck & Co., Inc. ### 2362199###Chair###Sr. Director, Statistical Programming###Merck & Co., Inc. ###
Chair: Jing Su, MS – Merck & Co., Inc.
### @@@ Neelima Thanneer, MS – BMS ### 2360663###Both###Executive Director, Head of Data Science and Clin Pharm Analysis & Reporting###BMS###
Both: Neelima Thanneer, MS – BMS
###
Emerging New Therapeutic Modalities
Favorite

Joy C. Hsu, PhD – Genentech ### 2360676###Moderator###Director, Clinical Pharmacology and Pharmacometrics###Genentech###
Moderator: Joy C. Hsu, PhD – Genentech
### @@@ Samira Khalili (she/her/hers) – Ionis ### 2363741###Speaker###Director of Pharmacokinetics and Clinical Pharmacology###Ionis###
Speaker: Samira Khalili (she/her/hers) – Ionis
### she/her/hers @@@ Donghua Yin, PhD – Pfizer ### 2363742###Speaker###Vice President, Head of Clinical Pharmacology, Pfizer Oncology Division###Pfizer###
Speaker: Donghua Yin, PhD – Pfizer
### @@@ Eric Masson, PharmD – Arvinas ### 2363743###Speaker###SVP, Early Clinical Development###Arvinas###
Speaker: Eric Masson, PharmD – Arvinas
###
Enabling Progress Against Alzheimer's Disease: Power of Diverse Pharmacometrics Approaches
Favorite

Julie A. Stone, PhD – Merck & Co., Inc. ### 2360716###Chair###Scientific Assoc. VP###Merck & Co., Inc.###
Chair: Julie A. Stone, PhD – Merck & Co., Inc.
### @@@ Youfang Cao, PhD – Eisai, Inc ### 2360717###Chair###Director of Pharmacometrics###Eisai, Inc###
Chair: Youfang Cao, PhD – Eisai, Inc
### @@@ Brian A. Willis, PhD (he/him/his) – Biogen ### 2360718###Speaker and Panelist###Head of Pharmacometrics###Biogen###
Speaker and Panelist: Brian A. Willis, PhD (he/him/his) – Biogen
### he/him/his @@@ Ivelina Gueorguieva, PhD (she/her/hers) – Eli Lilly and Company ### 2360719###Speaker and Panelist###Sr Director, Global PK/PD and Pharmacometrics###Eli Lilly and Company###
Speaker and Panelist: Ivelina Gueorguieva, PhD (she/her/hers) – Eli Lilly and Company
### she/her/hers @@@ Seth Robey, PhD (he/him/his) – Merck & Co., Inc. ### 2360720###Speaker and Panelist###Director, Quant. Pharmacology & Pharmacometrics###Merck & Co., Inc.###
Speaker and Panelist: Seth Robey, PhD (he/him/his) – Merck & Co., Inc.
### he/him/his @@@ Stephen Duffull, PhD (he/him/his) – Certara ### 2415651###Panelist###Senior Scientific Advisor###Certara###
Panelist: Stephen Duffull, PhD (he/him/his) – Certara
### he/him/his
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
Favorite

Michael Gertz, PhD (he/him/his) – F. Hoffmann-La Roche ### 2413383###Speaker###Expert Scientist###F. Hoffmann-La Roche###
Speaker: Michael Gertz, PhD (he/him/his) – F. Hoffmann-La Roche
### he/him/his
Ethical and Operational Considerations for Clinical Study Design and Conduct in Neonatal & Pregnancy Research
Favorite

Walter K. Kraft, MD (he/him/his) – Thomas Jefferson University ### 2360723###Speaker###Professor of Pharmacology, Surgery and Medicine###Thomas Jefferson University###
Speaker: Walter K. Kraft, MD (he/him/his) – Thomas Jefferson University
### he/him/his
Evolutionary and spatiotemporal response dynamics in metastatic colorectal cancers
Favorite

Yanguang Cao, PhD (he/him/his) – University of North Carolina at Chapel Hill ### 2360726###Speaker###Associate Professor###University of North Carolina at Chapel Hill###
Speaker: Yanguang Cao, PhD (he/him/his) – University of North Carolina at Chapel Hill
### he/him/his
Exposure, response, and baseline-factor triangle for large and small molecules: a search for the right angle
Favorite

Yulia Vugmeyster, PhD – Mural Oncology ### 2360706###Speaker###Executive Director, Clinical Pharmacology###Mural Oncology###
Speaker: Yulia Vugmeyster, PhD – Mural Oncology
###